Tanja Fehm

Professor

University Hospital Düsseldorf

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Medical Science Medical Science professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Frederick Wittke

Therapeutic Area Head, Vaccines European Clinical Development

SWITZERLAND

View details

Zaklina Kovacevic

University of New South Wales Science

AUSTRALIA

View details

Slavomir Krajnak

GERMANY

View details

hans neubauer

Head of Research (Prof. Dr. rer. nat. [W2])

Heinrich Heine University Düsseldorf

GERMANY

View details

Carsten Hagenbeck

University Hospital Düsseldorf

GERMANY

View details

Isabell Witzel

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tanja Fehm

Research Interests

Explore related searches

Contact this professor

Articles (10)

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046

Correction to: Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.

Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020).

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.

The effects of a music intervention during port catheter placement on anxiety and stress.

Does Nutrition Affect Endometriosis?

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.

Collaborators (6)

Frederick Wittke

Zaklina Kovacevic

Slavomir Krajnak

hans neubauer

Carsten Hagenbeck

Isabell Witzel

Make your next move.

Tanja Fehm

Research Interests

Explore related searches

Contact this professor

Articles (10)

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046

Correction to: Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression.

Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020).

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.

The effects of a music intervention during port catheter placement on anxiety and stress.

Does Nutrition Affect Endometriosis?

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.

Collaborators (6)

Frederick Wittke

Zaklina Kovacevic

Slavomir Krajnak

hans neubauer

Carsten Hagenbeck

Isabell Witzel

Make your next move.

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.